APA (7th ed.) Citation

EP, H., GS, F., JS, W., S, F., AM, O., ER, I., . . . BT, L. (2024). Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Targeted oncology, 19(6), 879. https://doi.org/10.1007/s11523-024-01102-8

Chicago Style (17th ed.) Citation

EP, Hamilton, et al. "Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial." Targeted Oncology 19, no. 6 (2024): 879. https://doi.org/10.1007/s11523-024-01102-8.

MLA (9th ed.) Citation

EP, Hamilton, et al. "Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial." Targeted Oncology, vol. 19, no. 6, 2024, p. 879, https://doi.org/10.1007/s11523-024-01102-8.